Patrick Troy, MD
Pulmonary Disease · Hartford, CTNPI 1033255229
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $266,578 of the $385,379 with a category attached, or 69.2%. Boston Scientific accounts for 63.8% of it on its own, with 37 other manufacturers making up the rest. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,087 payments — averaging $354.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$246K
- EKOS Corporation$45K
- Baxter Healthcare$39K
- AstraZeneca$30K
- Jazz Pharmaceuticals Inc.$12K
- Amgen$4K
- plus $9K from 32 others
What the payments were for
- Consulting fees$61,07916%
- Speaking & faculty fees$266,57869%
- Travel & lodging$31,6058%
- Food & beverage$23,7216%
- Education$2,3961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$188,781
- GENERAL - THERAPIES$36,205
- Renal - CRRT$22,961
- TEZSPIRE$21,825
- GENERAL VASCULAR INTERVENTION$21,798
- CLINICAL TRIAL PRODUCT$12,313
- AngioJet Ultra 5000A$11,218
- STARLING SYSTEM$10,015
- XYWAV$9,833
- ANGIOJET$5,920
- HYDROPICC$2,238
- HYDROMID$2,238
- HYDROPICC DUAL LUMEN$2,238
- VANNAS DEEP ACCESS VASCULAR SCISSORS$2,238
- Non-Franchise (NOF) - NonProduct$1,825
- XYREM$1,600
- GENERAL PAIN MANAGEMENT$806
- FASENRA$338
- BREZTRI$237
- GENERAL THROMBECTOMY$228
How this compares
$385,379 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 122 | $102,742 |
| TezspireTezepelumab-Ekko | 12 | $53,834 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $13,566 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,963 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,753 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $3,045 |
| Armodafinil | 18 | $1,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $790 |
| Azelastine Hcl | 31 | $483 |
| Montelukast Sodium | 26 | $361 |
| Clonazepam | 13 | $246 |
| Ipratropium Bromide | 15 | $202 |
| Zolpidem Tartrate | 23 | $140 |
| Prednisone | 20 | $101 |
| Fluticasone Propionate | 15 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $3,028 | $125,061172 claims |
| AstraZenecaTezspire | $30,028 | $53,83412 claims |
| Boehringer IngelheimSpiriva Respimat | $559 | $9,96317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Jeffrey NascimentoHartford$213K
- Daniel GerardiHartford$156K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
- Jordan PownerHartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.